Paper Details

  1. Home
  2. Paper Details

Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.

Author: AzrolanNeal, BreidingerSheila A, De SmetMarina, GottesdienerKeith M, GreenbergHoward E, HaazenWouter, IwamotoMarian, KostJames T, LaethemMartine, ManginEric C, PetryAmelia S, StoneJulie A, WagnerJohn A, WenningLarissa A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Raltegravir, a novel HIV-1 integrase strand transfer inhibitor, was assessed for its pharmacokinetic interaction with ritonavir and efavirenz. Ritonavir had a minimal effect on raltegravir pharmacokinetics, while efavirenz moderately reduced raltegravir exposure. However, the reduction caused by efavirenz was not clinically significant and did not require dose adjustments for raltegravir.
Paper Details　
Original Abstract of the Article :
Raltegravir is a novel human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor with potent in vitro activity against HIV-1 (95% inhibitory concentration = 31 nM in 50% human serum). The possible effects of ritonavir and efavirenz on raltegravir pharmacokinetics were separatel...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592871/

データ提供：米国国立医学図書館（NLM）

Raltegravir's Compatibility with HIV Treatment Regimens

This research explores the interaction of raltegravir, a powerful HIV-1 integrase inhibitor, with two commonly used antiretroviral drugs, ritonavir and efavirenz. The study investigates the potential influence of these drugs on the pharmacokinetic profile of raltegravir, assessing whether co-administration necessitates dose adjustments.

Raltegravir's Robustness in HIV Therapy

The study demonstrates that raltegravir's pharmacokinetic profile remains largely unaffected when co-administered with ritonavir. While a slight reduction in raltegravir levels was observed with efavirenz, the magnitude of this reduction is not clinically significant. This suggests that raltegravir can be safely co-administered with ritonavir or efavirenz without requiring dose adjustments.

Navigating the Complexities of HIV Treatment

Imagine HIV treatment as a delicate dance, where each drug plays a specific role in suppressing the virus. This research investigates the compatibility of raltegravir, a powerful HIV-1 integrase inhibitor, with other key players in the dance, ritonavir and efavirenz. The findings suggest that raltegravir can seamlessly integrate into this dance without disrupting the choreography, providing reassurance for patients and clinicians alike.

Dr.Camel's Conclusion

This study showcases the versatility of raltegravir as an effective HIV-1 integrase inhibitor, confirming its compatibility with commonly used antiretroviral drugs. The results provide valuable insight into the safe and effective co-administration of raltegravir within existing HIV treatment regimens.
Date :
  1. Date Completed 2009-01-27
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

18838589

DOI: Digital Object Identifier

PMC2592871

Related Literature

Article Analysis
・Effects of raltegravir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.